Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon. My name ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

“SPEVIGO’s new expanded indication constitutes a fundamental change for people ... Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of ...

"SPEVIGO's new expanded indication constitutes a fundamental ... Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an ...

"For patients living with GPP, their flares can be difficult to manage physically and emotionally," said Jensen Yeung, MD, FRCPC, dermatologist in Toronto, Ontario. "As a physician, it has been ...

"For patients living with GPP, their flares can be difficult to manage physically and emotionally," said Jensen Yeung, MD, FRCPC, dermatologist in Toronto, Ontario. "As a physician, it has been ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...